Previous Article | Next Article ![]()
Infection and Immunity, May 2001, p. 2888-2893, Vol. 69, No. 5
Departments of
Biotechnology,1 Infectious
Diseases,2 and Biochemistry and
Molecular Genetics,3 Israel Institute for
Biological Research, Ness-Ziona 74100, Israel
Received 30 November 2000/Returned for modification 3 January
2001/Accepted 30 January 2001
Vaccination by anthrax protective antigen (PA)-based vaccines
requires multiple immunization, underlying the need to develop more
efficacious vaccines or alternative vaccination regimens. In spite of
the vast use of PA-based vaccines, the definition of a marker for
protective immunity is still lacking. Here we describe studies designed
to help define such markers. To this end we have immunized guinea pigs
by different methods and monitored the immune response and the
corresponding extent of protection against a lethal challenge with
anthrax spores. Active immunization was performed by a single injection
using one of two methods: (i) vaccination with decreasing amounts of PA
and (ii) vaccination with constant amounts of PA that had been
thermally inactivated for increasing periods. In both studies a direct
correlation between survival and neutralizing-antibody titer was found
(r2 = 0.92 and 0.95, respectively). Most
significantly, in the two protocols a similar neutralizing-antibody
titer range provided 50% protection. Furthermore, in a complementary
study involving passive transfer of PA hyperimmune sera to naive
animals, a similar correlation between neutralizing-antibody titers and
protection was found. In all three immunization studies, neutralization
titers of at least 300 were sufficient to confer protection against a dose of 40 50% lethal doses (LD50) of virulent anthrax
spores of the Vollum strain. Such consistency in the correlation of
protective immunity with anti-PA antibody titers was not observed for
antibody titers determined by an enzyme-linked immunosorbent assay.
Taken together, these results clearly demonstrate that neutralizing antibodies to PA constitute a major component of the protective immunity against anthrax and suggest that this parameter could be used
as a surrogate marker for protection.
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.5.2888-2893.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Search for Correlates of Protective Immunity
Conferred by Anthrax Vaccine
*
Corresponding author: Mailing address: P.O. Box 19, 74100 Ness-Ziona, Israel. Phone: 972-8-9381518. Fax: 972-8-9401404. E-mail: baruch{at}iibr.gov.il.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|